after joining the study, you will have baseline examinations that may include blood tests, imaging, and a pet scan to document the extent of disease.

on the same day, you will receive the first chemotherapy cycle. the infusion includes:

brentuximab vedotin 1.8 mg per kilogram of body weight, given by intravenous infusion;

cyclophosphamide 1250 mg per square meter of body surface area, given by intravenous infusion;

doxorubicin hydrochloride 40 mg per square meter, given by intravenous infusion;

etoposide 150 mg per square meter, given by intravenous infusion;

dacarbazine citrate 250 mg, given by intravenous infusion;

in addition, you will take dexamethasone 40 mg by mouth on the day of infusion.

after completing a cycle, you will undergo a pet scan, which is an imaging test that shows how the cancer is responding to treatment.

the results of the pet scan are used to decide whether you will continue with additional cycles.

if the pet scan indicates that the disease is still active, you will receive another chemotherapy cycle with the same drugs and doses listed in step 1.

the schedule repeats every few weeks as directed by the study protocol.

you will continue to have a pet scan after each cycle to guide further treatment.

treatment stops after a minimum of four cycles and may continue up to a maximum of six cycles, depending on the pet scan results.

once the final cycle is finished, you will have a final pet scan and additional assessments to determine whether a complete remission has been achieved.

after treatment ends, you will be monitored for side effects and for any signs that the disease may return.

follow‑up visits may include blood tests, imaging, and questionnaires about your quality of life.